Back to Search
Start Over
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
- Source :
-
Clinical nuclear medicine [Clin Nucl Med] 2016 Jul; Vol. 41 (7), pp. 572-3. - Publication Year :
- 2016
-
Abstract
- An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.
- Subjects :
- Aged, 80 and over
Humans
Male
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant diagnostic imaging
Treatment Outcome
Dipeptides therapeutic use
Heterocyclic Compounds, 1-Ring therapeutic use
Lutetium therapeutic use
Prostatic Neoplasms, Castration-Resistant pathology
Prostatic Neoplasms, Castration-Resistant radiotherapy
Radioisotopes
Subjects
Details
- Language :
- English
- ISSN :
- 1536-0229
- Volume :
- 41
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Clinical nuclear medicine
- Publication Type :
- Academic Journal
- Accession number :
- 26909718
- Full Text :
- https://doi.org/10.1097/RLU.0000000000001200